| [1] |
de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors[J]. Cancer Cell, 2020,38(3):326-333.
doi: S1535-6108(20)30365-2
pmid: 32750319
|
| [2] |
Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management[J]. Crit Care, 2017,21(1):89.
doi: 10.1186/s13054-017-1678-1
URL
|
| [3] |
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020,70(2):86-104.
doi: 10.3322/caac.21596
URL
|
| [4] |
Kostine M, Chiche L, Lazaro E, et al. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge[J]. Rev Med Interne, 2017,38(8):513-525.
doi: S0248-8663(17)30025-5
pmid: 28214182
|
| [5] |
Joshi MN, Whitelaw BC, Palomar MT, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review[J]. Clin Endocrinol (Oxf), 2016,85(3):331-339.
doi: 10.1111/cen.13063
URL
|
| [6] |
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev, 2016,44:51-60.
doi: 10.1016/j.ctrv.2016.02.001
URL
|
| [7] |
Vita R, Guarneri F, Agah R, et al. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination[J]. Thyroid, 2014,24(2):390-394.
doi: 10.1089/thy.2013.0170
URL
|
| [8] |
Maekura T, Naito M, Tahara M, et al. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer[J]. In Vivo, 2017,31(5):1035-1039.
|
| [9] |
Kobayashi T, Iwama S, Yasuda Y, et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study[J]. J Endocr Soc, 2018,2(3):241-251.
doi: 10.1210/js.2017-00432
pmid: 29600292
|
| [10] |
Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J]. Ann Oncol, 2017,28(3):583-589.
doi: 10.1093/annonc/mdw640
pmid: 27998967
|
| [11] |
Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018,109(11):3583-3590.
doi: 10.1111/cas.13800
URL
|
| [12] |
Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms[J]. J Clin Endocrinol Metab, 2017,102(8):2770-2780.
doi: 10.1210/jc.2017-00448
pmid: 28609832
|
| [13] |
Sagiv O, Kandl TJ, Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor thera-py in cancer patients[J]. Ophthalmic Plast Reconstr Surg, 2019,35(1):50-52.
doi: 10.1097/IOP.0000000000001161
URL
|
| [14] |
Dalvin LA, Shields CL, Orloff M, et al. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects[J]. Retina, 2018,38(6):1063-1078.
doi: 10.1097/IAE.0000000000002181
URL
|
| [15] |
Muir CA, Clifton-Bligh RJ, Long GV, et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment[J]. J Clin Endocrinol Metab, 2021,106(9):e3704-e3713.
|
| [16] |
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017,5(1):95.
doi: 10.1186/s40425-017-0300-z
pmid: 29162153
|
| [17] |
Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020,6(1):38.
doi: 10.1038/s41572-020-0160-6
pmid: 32382051
|
| [18] |
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage Ⅲ melanoma[J]. N Engl J Med, 2018,378(19):1789-1801.
doi: 10.1056/NEJMoa1802357
URL
|
| [19] |
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717.
doi: 10.1200/JCO.2016.68.2005
URL
|
| [20] |
Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions[J]. Cancer Treat Rev, 2017,57:36-49.
doi: 10.1016/j.ctrv.2017.05.003
URL
|
| [21] |
U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0[R/OL]. 2010-06-14[2021-07-12]. https://www.researchgate.net/profile/Masayuki-Watanabe-8/publication/263706737_An_original_scoring_system_for_predicting_postoperative_morbidity_after_esophagectomy_for_esop-hageal_cancer/links/560e5db508ae48337515ee75/An-ori-ginal-scoring-system-for-predicting-postoperative-morbidity-after-esophagectomy-for-esophageal-cancer.pdf.
|
| [22] |
Girotra M, Hansen A, Farooki A, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management[J]. JNCI Cancer Spectr, 2018,2(3):pky021.
doi: 10.1093/jncics/pky021
URL
|
| [23] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社, 2019.
|
| [24] |
Arima H, Iwama S, Inaba H, et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society[J]. Endocr J, 2019,66(7):581-586.
doi: 10.1507/endocrj.EJ19-0163
URL
|
| [25] |
Ntali G, Kassi E, Alevizaki M. Endocrine sequelae of immune checkpoint inhibitors[J]. Hormones (Athens), 2017,16(4):341-350.
|
| [26] |
中华医学会内分泌学分会免疫内分泌学组. 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)[J]. 中华内分泌代谢杂志, 2021,37(1):1-16.
|
| [27] |
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017,28(suppl_4):iv119-iv142.
|
| [28] |
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients trea-ted with immune gheckpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018,36(17):1714-1768.
doi: 10.1200/JCO.2017.77.6385
pmid: 29442540
|
| [29] |
Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors[J]. J Immunother Cancer, 2019,7(1):306.
doi: 10.1186/s40425-019-0805-8
URL
|
